Time am CET

          Presenter                         

9:00 – 9.30

Registration and coffee.

9:30 – 9:45

Shaping Orexo's future: Strategic priorities and value creation.

Nikolaj Sørensen,                       

President and CEO. 

9:45 – 10:00

AmorphOX: A unique opportunity to transform drug delivery of biomolecules from unstable injectables to convenient nasal or tablet delivery in an established scalable commercial supply chain.

Robert Rönn, SVP and

Head of R&D/ Cecilia Coupland,                    

SVP and Head of Operations. 

                                   10:00 – 10:15

AmorphOX: Moving beyond nasal delivery in GLP-1s and expanding into new areas with significant market needs through preclinical innovation, and strategic partnerships.

Robert Rönn,

SVP and Head of R&D/ Lisa Moore, SVP, Product and Portfolio Strategy. 

10:15-10:30

OX640: Aiming for the best-in-class nasal epinephrine product improving stability, bioavailability and patient convenience to address the needs of severe allergy patients.

Robert Rönn/ Lisa Moore.

10:30-10:45

Break.

10:45-11:00

OX390: Developing the world's first medical countermeasure (MCM) to the rising threat from xylazine and medetomidine in collaboration with BARDA, a center within the US Department of Health and Human Services.

Edward Kim, SVP

and Chief Medical Officer.                        

11:00-11:15

Expert perspectives: Why counter-measures are needed for the emerging threats from xylazine, medetomidine, and fentanyl combinations.

Mark A. Smith, PhD 

Davidson College, NC, US. Dr Smith will attend through a prerecorded video.                

11:15-11:30

Building a viable business model through business development.

Fredrik Järrsten, EVP and CFO, Head of Business Development. 

11:30-12:00

Q&A, incl closing remarks by CEO. 

All presenters.

12 pm

Lunch & networking.